Thesis (Ph. D.)--Institute of Paper Chemistry, 1984. / Includes bibliographical references (p. 83-86).

Thesis (Ph. D.)--Institute of Paper Chemistry, 1979. / Includes bibliographical references (leaves 81-82).

Thesis (Ph. D.)--Institute of Paper Chemistry, 1981.

Thesis (Ph. D.)--Institute of Paper Chemistry, 1976. / Bibliography: leaves 93-95.

Thesis (Ph. D.)--Institute of Paper Chemistry, 1966. / Bibliography: leaves 82-84.

Thesis (Ph. D.)--Institute of Paper Chemistry, 1948. / Bibliography: leaves 78-80.

Thesis (Ph. D.)--Institute of Paper Chemistry, 1960. / Includes bibliographical references (leaves 72-73).

Coarse aggregate is often one of the largest volume occupying components in a portland cement concrete system. With increases in transportation costs and depletion of many of the aggregate sources currently in use the need to reevaluate the performance of aggregates in concrete has arisen. Current aggregate testing requirements for many organizations have not been updated in decades, even with the advancements in aggregate testing equipment that are currently available. This research project investigates current used and potential test methods for evaluating coarse aggregate for use in portland cement concrete. Testing focused on determining the most appropriate aggregate property to evaluate and then determining the correlation to mechanical concrete properties. Relationships between potential aggregate tests and currently used aggregate tests were evaluated to determine if compatible relationships between methods were evident. For this purpose concrete mixtures were made at a fixed aggregate volume to establish if a link was evident between aggregate test properties and concrete. To establish a link between laboratory and real world performance field sites with known distress were visited to better establish limits for aggregate testing requirements. Results obtained provided the basis for recommendations for testing requirements and limits to be used for aggregates in portland cement concrete. / text

<p>Growth factors and their receptors coordinate neuronal differentiation during development, yet their roles in the embyronal tumor neuroblastoma, where differentiation is a validated treatment strategy, remain unclear. The neuroblastoma tumor stroma is thought to suppress neuroblast growth via release of soluble differentiating factors. Here we identify critical components of the differentiating stroma secretome and describe preclinical testing of a novel therapeutic strategy based on their mechanism of action.</p><p>Expression of heparan sulfate proteoglycans (HSPGs), including T&#946;RIII, GPC1, GPC3, SDC3, and SDC4, is decreased in neuroblastoma, high in the stroma, and suppresses tumor growth. High expression of T&#946;RIII, GPC1, and SDC3 is associated with improved patient prognosis. HSPGs signal via heparan sulfate binding to FGFR1 and FGF2, which leads to phosphorylation of FGFR1 and Erk MAPK, and upregulation of the transcription factor inhibitor of DNA binding 1 (Id1). Surface expression and treatment with soluble HSPGs promotes neuroblast differentiation via this signaling complex. Expression of individual HSPGs positively correlates with Id1 expression in neuroblastoma patient samples and multivariate regression demonstrates that expression of HSPGs as a group positively correlates with Id1 expression, underscoring the clinical relevance of this pathway. HSPGs also enhance differentiation from FGF2 released by the stroma and FGF2 is identified as a potential serum prognostic biomarker in neuroblastoma patients. </p><p>The anticoagulant heparin has similar differentiating effects to HSPGs, decreasing neuroblast proliferation and reducing tumor growth while extending survival in an orthotopic xenograft model of neuroblastoma. Dissection of individual sulfation sites identifies 2-O-, 3-O-de-sulfated heparin (ODSH) as a differentiating agent that suppresses orthotopic xenograft growth and metastasis in two models while avoiding anticoagulation. These studies form the preclinical rationale for a multicenter clinical trial currently being proposed.</p><p>In conclusion, these studies translate mechanistic insights in neuroblast HSPG function to identify heparins as differentiating agents for clinical development in neuroblastoma, while demonstrating that tumor stroma biology can inform design of targeted molecular therapeutics.</p> / Dissertation

At hydrothermal vents, thermal and chemical gradients generated by the mixing of hydrothermal fluids with seawater provide diverse niches for prokaryotic communities. To date, our knowledge of environmental factors that shape bacterial and archaeal community composition and metabolic activities across these gradients within the active sulfide structures is limited. While many studies have laid the foundation for our understanding of the extent of diversity in relation to varying hydrothermal settings, few studies exists regarding the detailed spatial relationships between vent geochemistry and the abundance, distribution, and metabolic characteristics of the endolithic hosted communities. Even fewer data have been generated on the magnitude of metabolic rates and factors controlling the kinetics of these reactions have not been well constrained.